Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 54.4% in June

Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the recipient of a large decrease in short interest in June. As of June 30th, there was short interest totaling 6,731 shares, a decrease of 54.4% from the June 15th total of 14,757 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 70,886 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Get Exicure alerts:

Get Our Latest Research Report on XCUR

Exicure Trading Up 2.4%

Shares of XCUR traded up $0.04 during midday trading on Wednesday, reaching $1.76. 8,429,903 shares of the company were exchanged, compared to its average volume of 185,257. Exicure has a 1-year low of $1.57 and a 1-year high of $9.50. The stock has a 50-day moving average price of $2.64 and a 200-day moving average price of $3.83. The company has a market cap of $11.22 million, a price-to-earnings ratio of -1.14 and a beta of 3.61.

Exicure (NASDAQ:XCUR – Get Free Report) last posted its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.31.

About Exicure

(Get Free Report)

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.

Featured Stories

• Five stocks we like better than Exicure
• Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger
• Alphabet’s AI Spending Question Looms Over Q2 Earnings
• 3 Small-Cap Stocks Trading Under $10 With Room to Run
• CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.